Global Ophthalmic Drugs Market Forecast 2023-2032

The global ophthalmic drugs market is predicted to project a CAGR of 6.09% during the forecast period, 2023-2032. The market growth is accredited to the vulnerability of the aging population to eye conditions associated with age, progress in drug delivery technologies, increasing incidence of eye diseases and disorders, and positive reimbursement policies implemented by healthcare systems.

MARKET INSIGHTS

Ophthalmic drugs play a crucial role in addressing a spectrum of eye-related conditions, including but not limited to glaucoma, age-related macular degeneration (AMD), dry eye syndrome, and diabetic retinopathy. Ophthalmic drugs encompass a diverse range of drug classes, including anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, and others. These drugs are tailored to address specific disease indications such as inflammation, infections, elevated intraocular pressure, and retinal disorders.

The global increase in the prevalence of eye diseases and disorders can be attributed to a combination of demographic, lifestyle, and environmental factors. One contributing factor is the widespread usage of digital devices, such as smartphones, computers, and tablets, leading to heightened exposure to the blue light emitted by these screens. Prolonged exposure to this blue light can result in digital eye strain, manifesting as symptoms like dry eyes, eye fatigue, and discomfort. Although not a disease on its own, digital eye strain has the potential to worsen existing eye conditions and adversely affect visual comfort.

However, patent expirations and the entry of generic drugs pose challenges to market growth. Untapped potential in emerging economies offers a growth avenue for market players.

REGIONAL INSIGHTS

The global ophthalmic drugs market growth evaluation includes the geographical analysis of North America, Europe, Asia-Pacific, and Rest of World. Asia-Pacific is the fastest-growing region in the global market, driven by various factors such as the increasing prevalence of eye disorders, rising aging population, and advancements in pharmaceutical research and development.

COMPETITIVE INSIGHTS

The market for ophthalmic drugs on a global scale is characterized by intense competition, as various pharmaceutical companies vie for a share of the market. Major players dedicate substantial resources to research and development endeavors aimed at introducing novel drugs and therapies, fostering a continuous cycle of innovation. Some of the leading companies in the market include AbbVie Inc, Genentech Inc, Bausch Health Companies Inc, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 74069

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
- 2.5.2. GROWING DEMAND FOR COMBINATION THERAPIES
- 2.5.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
- 2.5.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. AGING POPULATION'S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
- 3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
- 3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
- 3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
3.2. KEY RESTRAINTS
- 3.2.1. DELAY IN DRUG APPROVALS
- 3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
4.2. TECHNOLOGY SNAPSHOT
- 4.2.1. BIOLOGICS
- 4.2.2. CELL THERAPY
- 4.2.3. GENE THERAPY
- 4.2.4. DRUG DELIVERY
- 4.2.5. SMALL MOLECULE
- 4.2.6. OTHER TECHNOLOGIES
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
- 4.4.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
- 4.4.2. GROWTH PROSPECT MAPPING FOR ITALY
- 4.4.3. GROWTH PROSPECT MAPPING FOR INDIA
- 4.4.4. GROWTH PROSPECT MAPPING FOR THE MIDDLE EAST & AFRICA
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK

5. MARKET BY INDICATION

5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGIES
5.4. RETINAL DISORDER
- 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
- 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
- 5.4.3. DIABETIC RETINOPATHY
- 5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATIONS

6. MARKET BY TYPE

6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DOSAGE FORM

7.1. GELS
7.2. EYE SOLUTIONS & SUSPENSIONS
7.3. CAPSULES & TABLETS
7.4. EYE DROPS
7.5. OINTMENTS

8. MARKET BY THERAPEUTIC CLASS

8.1. ANTI-GLAUCOMA
8.2. ANTI-INFECTION
8.3. ANTI-INFLAMMATORY
8.4. ANTI-ALLERGY
8.5. OTHER THERAPEUTIC CLASSES

9. MARKET BY DISTRIBUTION CHANNEL

9.1. HOSPITAL PHARMACIES
9.2. DRUG STORES
9.3. ONLINE PHARMACIES
9.4. OTHER DISTRIBUTION CHANNELS

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. NORTH AMERICA OPHTHALMIC DRUGS MARKET DRIVERS
- 10.1.3. NORTH AMERICA OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.1.4. KEY PLAYERS IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. UNITED STATES
  - 10.1.5.1.1. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.2. CANADA
  - 10.1.5.2.1. CANADA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
10.2. EUROPE
- 10.2.1. MARKET SIZE & ESTIMATES
- 10.2.2. EUROPE OPHTHALMIC DRUGS MARKET DRIVERS
- 10.2.3. EUROPE OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.2.4. KEY PLAYERS IN EUROPE OPHTHALMIC DRUGS MARKET
- 10.2.5. COUNTRY ANALYSIS
  - 10.2.5.1. UNITED KINGDOM
  - 10.2.5.1.1. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.2. GERMANY
  - 10.2.5.2.1. GERMANY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.3. FRANCE
  - 10.2.5.3.1. FRANCE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.4. ITALY
  - 10.2.5.4.1. ITALY OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.5. SPAIN
  - 10.2.5.5.1. SPAIN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.6. BELGIUM
  - 10.2.5.6.1. BELGIUM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.7. POLAND
  - 10.2.5.7.1. POLAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.2.5.8. REST OF EUROPE
  - 10.2.5.8.1. REST OF EUROPE OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
10.3. ASIA-PACIFIC
- 10.3.1. MARKET SIZE & ESTIMATES
- 10.3.2. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET DRIVERS
- 10.3.3. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.3.4. KEY PLAYERS IN ASIA-PACIFIC OPHTHALMIC DRUGS MARKET
- 10.3.5. COUNTRY ANALYSIS
  - 10.3.5.1. CHINA
  - 10.3.5.1.1. CHINA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.2. JAPAN
  - 10.3.5.2.1. JAPAN OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.3. INDIA
  - 10.3.5.3.1. INDIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.4. SOUTH KOREA
  - 10.3.5.4.1. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.5. INDONESIA
  - 10.3.5.5.1. INDONESIA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.6. THAILAND
  - 10.3.5.6.1. THAILAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.7. VIETNAM
  - 10.3.5.7.1. VIETNAM OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.8. AUSTRALIA & NEW ZEALAND
  - 10.3.5.8.1. AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.3.5.9. REST OF ASIA-PACIFIC
  - 10.3.5.9.1. REST OF ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
10.4. REST OF WORLD
- 10.4.1. MARKET SIZE & ESTIMATES
- 10.4.2. REST OF WORLD OPHTHALMIC DRUGS MARKET DRIVERS
- 10.4.3. REST OF WORLD OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.4.4. KEY PLAYERS IN REST OF WORLD OPHTHALMIC DRUGS MARKET
- 10.4.5. REGIONAL ANALYSIS
  - 10.4.5.1. LATIN AMERICA
  - 10.4.5.1.1. LATIN AMERICA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.4.5.2. MIDDLE EAST & AFRICA
  - 10.4.5.2.1. MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
- 11.2.1. ABBVIE INC
  - 11.2.1.1. COMPANY OVERVIEW
  - 11.2.1.2. PRODUCTS & SERVICES
  - 11.2.1.3. STRENGTHS & CHALLENGES
- 11.2.2. ACCUTOME INC
  - 11.2.2.1. COMPANY OVERVIEW
  - 11.2.2.2. PRODUCTS & SERVICES
  - 11.2.2.3. STRENGTHS & CHALLENGES
- 11.2.3. BAUSCH HEALTH COMPANIES INC
  - 11.2.3.1. COMPANY OVERVIEW
  - 11.2.3.2. PRODUCTS & SERVICES
  - 11.2.3.3. STRENGTHS & CHALLENGES
- 11.2.4. GENENTECH INC
  - 11.2.4.1. COMPANY OVERVIEW
  - 11.2.4.2. PRODUCTS & SERVICES
  - 11.2.4.3. STRENGTHS & CHALLENGES
- 11.2.5. JOHNSON & JOHNSON
  - 11.2.5.1. COMPANY OVERVIEW
  - 11.2.5.2. PRODUCTS & SERVICES
  - 11.2.5.3. STRENGTHS & CHALLENGES
- 11.2.6. THEA PHARMA INC
  - 11.2.6.1. COMPANY OVERVIEW
  - 11.2.6.2. PRODUCTS & SERVICES
  - 11.2.6.3. STRENGTHS & CHALLENGES
- 11.2.7. NOVARTIS AG
  - 11.2.7.1. COMPANY OVERVIEW
  - 11.2.7.2. PRODUCTS & SERVICES
  - 11.2.7.3. STRENGTHS & CHALLENGES
- 11.2.8. PFIZER INC
  - 11.2.8.1. COMPANY OVERVIEW
  - 11.2.8.2. PRODUCTS & SERVICES
  - 11.2.8.3. STRENGTHS & CHALLENGES
- 11.2.9. REGENERON PHARMACEUTICALS INC
  - 11.2.9.1. COMPANY OVERVIEW
  - 11.2.9.2. PRODUCTS & SERVICES
  - 11.2.9.3. STRENGTHS & CHALLENGES
- 11.2.10. SANTEN PHARMACEUTICAL CO LTD
  - 11.2.10.1. COMPANY OVERVIEW
  - 11.2.10.2. PRODUCTS & SERVICES
  - 11.2.10.3. STRENGTHS & CHALLENGES
- 11.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
  - 11.2.11.1. COMPANY OVERVIEW
  - 11.2.11.2. PRODUCTS & SERVICES
  - 11.2.11.3. STRENGTHS & CHALLENGES
- 11.2.12. TEVA PHARMACEUTICALS INDUSTRIES LTD
  - 11.2.12.1. COMPANY OVERVIEW
  - 11.2.12.2. PRODUCTS & SERVICES
  - 11.2.12.3. STRENGTHS & CHALLENGES